Lys221
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys221  -  GTF2I (human)

Site Information
sCGPIkVkTEPTEDS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 40724403

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 4 ) , mutation of modification site ( 1 )
Disease tissue studied:
liver cancer ( 1 ) , hepatocellular carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on GTF2I:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 )
Inhibit interaction with:
HDAC3 (human) ( 1 )

References 

1

Tu J, et al. (2015) Functional Proteomics Study Reveals SUMOylation of TFII-I is Involved in Liver Cancer Cell Proliferation. J Proteome Res 14, 2385-97
25869096   Curated Info

2

Hendriks IA, et al. (2014) Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol 21, 927-36
25218447   Curated Info

3

Impens F, Radoshevich L, Cossart P, Ribet D (2014) Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli. Proc Natl Acad Sci U S A 111, 12432-7
25114211   Curated Info

4

Tammsalu T, et al. (2014) Proteome-wide identification of SUMO2 modification sites. Sci Signal 7, rs2
24782567   Curated Info